Amlodipine besylate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for amlodipine besylate and what is the scope of freedom to operate?

Amlodipine besylate is the generic ingredient in eighteen branded drugs marketed by Synthon Pharms, Accord Hlthcare, Alkem, Amneal Pharms Ny, Apotex, Aurobindo Pharma, China Resources, Cipla, Epic Pharma Llc, Gedeon Richter Usa, Genpharm, Hebei Changshan, Hikma, Hikma Pharms, Invagen Pharms, Lupin, Macleods Pharms Ltd, Mylan, Orchid Hlthcare, Oxford Pharms, Polygen Pharms, Puracap Pharm, Sovereign Pharms, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Sunshine Lake, Teva, Torrent Pharms, Unichem Labs Ltd, Upsher Smith Labs, Watson Labs, Wockhardt, Yaopharma Co Ltd, Zydus Pharms Usa, Pfizer, Dr Reddys, Zydus Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Inc, Lupin Pharms, Par Pharm, Teva Pharms, Watson Labs Inc, Novartis, Coeptis, Par Pharm Inc, Teva Pharms Usa, Torrent, Daiichi Sankyo, Lupin Ltd, Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic Pharms Ltd, Alkem Labs Ltd, Glenmark Pharms Ltd, Jubilant Generics, Micro Labs, Sciegen Pharms Inc, Adhera, Boehringer Ingelheim, and Novel Labs Inc, and is included in ninety-nine NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amlodipine besylate has four patent family members in four countries.

There are fifty drug master file entries for amlodipine besylate. Fifty-four suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for amlodipine besylate

International Patents:	4
US Patents:	8
Tradenames:	18
Applicants:	63
NDAs:	99
Drug Master File Entries:	50
Suppliers / Packagers:	54
Bulk Api Vendors:	90
Clinical Trials:	52
Patent Applications:	4,210
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for amlodipine besylate
Drug Sales Revenues:	Drug sales revenues for amlodipine besylate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amlodipine besylate
DailyMed Link:	amlodipine besylate at DailyMed

See drug prices for amlodipine besylate

Drug Sales Revenue Trends for amlodipine besylate

See drug sales revenues for amlodipine besylate

Recent Clinical Trials for amlodipine besylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shanghai Jiao Tong University School of Medicine	Phase 4
Conjupro Biotherapeutics	Phase 1
CSPC Ouyi Pharmaceutical Co., Ltd.	Phase 1

See all amlodipine besylate clinical trials

Recent Litigation for amlodipine besylate

Identify potential future generic entrants

District Court Litigation

Case Name	Date
Edwards Lifesciences AG v. CoreValve, Inc.	2014-04-14
Pfizer Inc. v. Ranbaxy Laboratories Limited	2008-03-24
Plaintiff(s) v. Defendant(s)	2008-01-31

See all amlodipine besylate litigation

Generic filers with tentative approvals for AMLODIPINE BESYLATE

Applicant	Application No.	Strength	Dosage Form
Start Trial	Start Trial	EQ 10MG BASE	TABLET;ORAL
Start Trial	Start Trial	EQ 5MG BASE	TABLET;ORAL
Start Trial	Start Trial	EQ 2.5MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for amlodipine besylate

Drug Class	Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists

Synonyms for amlodipine besylate

(R,S,)3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulphonate
111470-99-6
2-(2-Aminoethoxy)methyl-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic Acid 3-Ethyl 5-Methyl Ester Benzenesulfona
2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid O3-ethyl ester O5-methyl ester; benzenesulfonic acid
2-[(2-Aminoethoxy)-methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzene sulfonate
2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzenesulfonate
2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine benzenesulfonate
3-Ethyl 5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulfonate
3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate
3-Ethyl 5-Methyl 2-(2-Aminoethoxy)methyl-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Benzenesulfonate
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (+-)-, monobenzenesulfonate
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, monobenzenesulfonate
470A996
A802368
AB0012646
AB2000306
AC-079
AC1L1TCT
AC1Q6WSZ
AK122586
AKOS001260256
AKOS016340493
Amcard
Amdepin
Amdipin
Amlodin
Amlodipine (besylate)
Amlodipine benzenesulfonate
Amlodipine benzenesulphonate
Amlodipine besilate
Amlodipine besilate (JP17)
Amlodipine besylate (Norvasc)
Amlodipine besylate (USAN)
Amlodipine besylate [USAN:USP]
Amlodipine besylate [USAN]
Amlodipine besylate, >=98% (HPLC)
Amlodipine besylate, European Pharmacopoeia (EP) Reference Standard
Amlodipine besylate, Pharmaceutical Secondary Standard; Certified Reference Material
Amlodipine besylate, racemic mixture
Amlodipine besylate, United States Pharmacopeia (USP) Reference Standard
Amlodipine for peak identification, European Pharmacopoeia (EP) Reference Standard
amlodipine; benzenesulfonic acid
Amlogard
Amlopin
Amlosyn
AN-7254
Antacal
AOB5215
API0005435
Astudar
AX8246764
BCP21993
BCP9000059
benzenesulfonic acid; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
benzenesulfonic acid; O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
benzenesulfonic acid; O3-ethyl O5-methyl 2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
C20H25ClN2O5.C6H6O3S
C26H31ClN2O8S
CA0135
Cardiorex
CAS-111470-99-6
CCG-39531
CHEBI:2669
CHEMBL1200402
CHEMBL3193637
CHEMBL3207778
Cordarene
CS-3988
D00615
DSSTox_CID_23909
DSSTox_GSID_43909
DSSTox_RID_80087
DTXSID2043909
F6170-0024
FT-0082675
FT-0622301
HMS2094E13
HMS2232D22
HMS2235B19
HMS3269B19
HMS3372O18
HMS3373F15
HSDB 7079
HY-B0317B
I06-0736
Istin
Istin;Norvasc;Norvasc
J10223
J10238
KB-295583
KBio2_001053
KBio2_003621
KBio2_006189
KBioSS_001053
KS-1029
LS-131175
MCULE-3638128556
MFCD00864687
MFCD00887594
MLS001361394
MolPort-001-759-081
Monopina
Myodura
NCGC00095835-01
NCGC00165957-04
Norlopin
Norvas
Norvasc (TN)
Norvask
NSC-758922
NSC758922
Pelmec
Pharmakon1600-01505202
Q-101934
Q-200627
r-amlodipine
s1813
SCHEMBL41282
SMR000875356
Spectrum_000573
SPECTRUM1505202
SR-05000001461-2
Stamlo
SW198880-2
Tensivask
Terloc
TL8000339
Tox21_111525
Tox21_113476
UK 48340-26
UK-48,340
UK-48,340-26
UK-48340-26
UK-4834026
VU0244594-3
ZPBWCRDSRKPIDG-UHFFFAOYSA-N

Paragraph IV (Patent) Challenges for AMLODIPINE BESYLATE

Tradename	Dosage	Ingredient	NDA	Submissiondate
NORVASC	TABLET;ORAL	amlodipine besylate	019787

US Patents and Regulatory Information for amlodipine besylate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	207762-011	Jan 11, 2019		DISCN	No	No	Start Trial	Start Trial				Start Trial
Sun Pharm Inds Inc	AMLODIPINE BESYLATE	amlodipine besylate	TABLET;ORAL	078231-002	Nov 30, 2007		DISCN	No	No	Start Trial	Start Trial				Start Trial
Sciegen Pharms Inc	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	209010-001	Dec 3, 2018	AB	RX	No	No	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for amlodipine besylate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	NORVASC	amlodipine besylate	TABLET;ORAL	019787-003	Jul 31, 1992	Start Trial	Start Trial
Pfizer	NORVASC	amlodipine besylate	TABLET;ORAL	019787-001	Jul 31, 1992	Start Trial	Start Trial
Pfizer	NORVASC	amlodipine besylate	TABLET;ORAL	019787-001	Jul 31, 1992	Start Trial	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for amlodipine besylate

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	037565	Start Trial
World Intellectual Property Organization (WIPO)	03043635	Start Trial
Australia	2002343257	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for amlodipine besylate

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1507558	12C0033	France	Start Trial	PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
0443983	C300445	Netherlands	Start Trial	PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
1507558	2012/018	Ireland	Start Trial	PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.